These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35961460)

  • 1. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
    Caldwell TM; Ahn YM; Bulfer SL; Leary CB; Hood MM; Lu WP; Vogeti L; Vogeti S; Kaufman MD; Wise SC; Le Bourdonnec B; Smith BD; Flynn DL
    Bioorg Med Chem Lett; 2022 Oct; 74():128928. PubMed ID: 35961460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
    Smith BD; Kaufman MD; Wise SC; Ahn YM; Caldwell TM; Leary CB; Lu WP; Tan G; Vogeti L; Vogeti S; Wilky BA; Davis LE; Sharma M; Ruiz-Soto R; Flynn DL
    Mol Cancer Ther; 2021 Nov; 20(11):2098-2109. PubMed ID: 34433663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib.
    Gelderblom H; Razak AA; Taylor MH; Bauer TM; Wilky B; Martin-Broto J; Gonzalez AF; Rutkowski P; Szostakowski B; Alcindor T; Saleh R; Genta S; Stacchiotti S; van de Sande M; Wagner AJ; Bernthal N; Davis LE; Vuky J; Tait C; Matin B; Narasimhan S; Sharma MG; Ruiz-Soto R; Sherman ML; Tap WD
    Clin Cancer Res; 2024 Sep; 30(18):3996-4004. PubMed ID: 38995311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor.
    Tap WD; Sharma MG; Vallee M; Smith BD; Sherman ML; Ruiz-Soto R; de Sande MV; Randall RL; Bernthal NM; Gelderblom H
    Future Oncol; 2024 Mar; 20(10):593-601. PubMed ID: 37593881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment updates on tenosynovial giant cell tumor.
    Palmerini E; Staals EL
    Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
    Chan AS; Katiyar V; Dy P; Singh V
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Gelderblom H; Bhadri V; Stacchiotti S; Bauer S; Wagner AJ; van de Sande M; Bernthal NM; López Pousa A; Razak AA; Italiano A; Ahmed M; Le Cesne A; Tinoco G; Boye K; Martín-Broto J; Palmerini E; Tafuto S; Pratap S; Powers BC; Reichardt P; Casado Herráez A; Rutkowski P; Tait C; Zarins F; Harrow B; Sharma MG; Ruiz-Soto R; Sherman ML; Blay JY; Tap WD;
    Lancet; 2024 Jun; 403(10445):2709-2719. PubMed ID: 38843860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
    van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
    J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
    Brahmi M; Vinceneux A; Cassier PA
    Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG; Gronchi A; Stacchiotti S
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
    Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
    Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches.
    Spierenburg G; van der Heijden L; van Langevelde K; Szuhai K; Bovée JVGM; van de Sande MAJ; Gelderblom H
    Expert Opin Ther Targets; 2022 Apr; 26(4):333-345. PubMed ID: 35443852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-Derived Tumor Xenografts Plus Ex Vivo Models Enable Drug Validation for Tenosynovial Giant Cell Tumors.
    Tang F; Tie Y; Hong WQ; He X; Min L; Zhou Y; Luo Y; Chen SY; Yang JY; Shi HH; Wei XW; Tu CQ
    Ann Surg Oncol; 2021 Oct; 28(11):6453-6463. PubMed ID: 33748895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
    Staals EL; Ferrari S; Donati DM; Palmerini E
    Eur J Cancer; 2016 Aug; 63():34-40. PubMed ID: 27267143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of Imatinib Mesylate in diffuse-type Tenosynovial Giant Cell Tumours on MR imaging and PET-CT.
    Mastboom MJL; Lips W; van Langevelde K; Mifsud M; Ng C; McCarthy CL; Athanasou NA; Gibbons CLMH; van de Sande MAJ
    Surg Oncol; 2020 Dec; 35():261-267. PubMed ID: 32932224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor.
    Noguchi R; Yoshimatsu Y; Ono T; Sei A; Hirabayashi K; Ozawa I; Kikuta K; Kondo T
    Hum Cell; 2021 Jan; 34(1):254-259. PubMed ID: 32886306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
    Palmerini E; Longhi A; Donati DM; Staals EL
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vimseltinib for tenosynovial giant cell tumour.
    Urakawa H; Imagama S
    Lancet; 2024 Jun; 403(10445):2665-2667. PubMed ID: 38843859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.